JP2023539736A5 - - Google Patents
Info
- Publication number
- JP2023539736A5 JP2023539736A5 JP2023513407A JP2023513407A JP2023539736A5 JP 2023539736 A5 JP2023539736 A5 JP 2023539736A5 JP 2023513407 A JP2023513407 A JP 2023513407A JP 2023513407 A JP2023513407 A JP 2023513407A JP 2023539736 A5 JP2023539736 A5 JP 2023539736A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- antigen
- composition according
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070209P | 2020-08-25 | 2020-08-25 | |
| US63/070,209 | 2020-08-25 | ||
| PCT/US2021/047610 WO2022046942A1 (en) | 2020-08-25 | 2021-08-25 | Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539736A JP2023539736A (ja) | 2023-09-19 |
| JP2023539736A5 true JP2023539736A5 (enExample) | 2024-07-23 |
Family
ID=77693641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513407A Pending JP2023539736A (ja) | 2020-08-25 | 2021-08-25 | 拮抗性ｃｄ４０モノクローナル抗体で自己免疫性疾患を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230331860A1 (enExample) |
| EP (1) | EP4204099A1 (enExample) |
| JP (1) | JP2023539736A (enExample) |
| KR (1) | KR20230054451A (enExample) |
| CN (1) | CN116322761A (enExample) |
| AU (1) | AU2021331087A1 (enExample) |
| BR (1) | BR112023002803A2 (enExample) |
| CA (1) | CA3190727A1 (enExample) |
| IL (1) | IL300765A (enExample) |
| MX (1) | MX2023002093A (enExample) |
| WO (1) | WO2022046942A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| TWI788340B (zh) * | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| KR20200074993A (ko) * | 2017-11-03 | 2020-06-25 | 노파르티스 아게 | 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체 |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
-
2021
- 2021-08-25 US US18/042,553 patent/US20230331860A1/en active Pending
- 2021-08-25 IL IL300765A patent/IL300765A/en unknown
- 2021-08-25 AU AU2021331087A patent/AU2021331087A1/en active Pending
- 2021-08-25 MX MX2023002093A patent/MX2023002093A/es unknown
- 2021-08-25 BR BR112023002803A patent/BR112023002803A2/pt unknown
- 2021-08-25 CN CN202180052235.3A patent/CN116322761A/zh active Pending
- 2021-08-25 JP JP2023513407A patent/JP2023539736A/ja active Pending
- 2021-08-25 KR KR1020237009804A patent/KR20230054451A/ko active Pending
- 2021-08-25 WO PCT/US2021/047610 patent/WO2022046942A1/en not_active Ceased
- 2021-08-25 CA CA3190727A patent/CA3190727A1/en active Pending
- 2021-08-25 EP EP21766803.7A patent/EP4204099A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517236A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| CN115925919A (zh) | 改进的血清白蛋白结合免疫球蛋白可变结构域 | |
| JP7160533B2 (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| EP3224280A1 (en) | Vedolizumab for the treatment of fistulizing crohn's disease | |
| JP2022513386A5 (enExample) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2025501978A5 (enExample) | ||
| JP2022541591A5 (enExample) | ||
| CN116997363A (zh) | 抗体药物偶联物治疗癌症的方法及用途 | |
| JP2023520771A5 (enExample) | ||
| JP2013193995A (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| CN115501347A (zh) | 抗her2抗体药物偶联物和parp抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| EP4615867A1 (en) | Methods for the treatment of cardiovascular disease | |
| CN118382463A (zh) | 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 | |
| JP2024540435A5 (enExample) | ||
| JP2024515266A (ja) | 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体 | |
| JP2023539736A5 (enExample) | ||
| JP2023506779A5 (enExample) | ||
| JP2023546504A5 (enExample) | ||
| JP2023507981A5 (enExample) | ||
| CN114423455A (zh) | 用于治疗系统性硬化症的药物组合物 | |
| IL292493B1 (en) | Stable aqueous anti-TFPI antibody formulation | |
| US20220267474A1 (en) | Methods for improving circulation and treating cardiovascular disease |